Cancer Treatment Drugs Consumption Market Synopsis:
In this report, LP Information covers the present scenario with the base year being 2017 and the growth prospects of global Cancer Treatment Drugs market for 20182023.
Cancer Treatment Drugs are used to treat malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy Biologic Therapy, Hormonal Therapy and Others.
The classification of cancer treatment drugs includes chemotherapy, targeted therapy, immunotherapy, hormonal therapy and others, and the revenue proportion of chemotherapy in 2016 is about 51%.
Cancer treatment drugs are widely used for blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, respiratory/lung cancer and other cancers. Amongst these different cancer types, blood cancer was the largest revenue generating segment in 2016, and the revenue market share is about 22%. The growth of blood cancer segment is majorly due to the high cost of the drugs used to treat blood cancer.
Europe region is the largest supplier of cancer treatment drugs, with a revenue market share nearly 47% in 2016. North America is the second largest supplier of cancer treatment drugs, enjoying revenue market share nearly 34% in 2016. Japan region is also holding the monopoly position around the world.
North America is the largest consumption place, with the consumption market share nearly 43% in 2016, and North America market size reached 46 billion USD. China, India and Southeast Asia are the emerging markets, and enjoy higher grow rate.
Over the next five years, LPILP Information projects that Cancer Treatment Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Treatment Drugs market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy Biologic Therapy
Others
Segmentation by application:
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Roche
Novartis
Celgene
BristolMyers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co.
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
Merck KGaA
Ipsen
AbbVie
Gilead Sciences
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Cancer Treatment Drugs consumption value & volume by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Cancer Treatment Drugs market by identifying its various subsegments.
Focuses on the key global Cancer Treatment Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Cancer Treatment Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industryspecific challenges and risks.
To project the consumption of Cancer Treatment Drugs submarkets, with respect to key regions along with their respective key countries.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
